Cargando…
Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma
PURPOSE: Isocitrate dehydrogenase 1 (IDH1) mutations are the most common genetic abnormalities in low-grade gliomas and secondary glioblastomas. Glioma patients with these mutations had better clinical outcomes. However, the effect of IDH1 mutation on drug sensitivity is still under debate. MATERIAL...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053882/ https://www.ncbi.nlm.nih.gov/pubmed/33070553 http://dx.doi.org/10.4143/crt.2020.506 |
_version_ | 1783680209033101312 |
---|---|
author | Lin, Lin Cai, Jinquan Tan, Zixiao Meng, Xiangqi Li, Ruiyan Li, Yang Jiang, Chuanlu |
author_facet | Lin, Lin Cai, Jinquan Tan, Zixiao Meng, Xiangqi Li, Ruiyan Li, Yang Jiang, Chuanlu |
author_sort | Lin, Lin |
collection | PubMed |
description | PURPOSE: Isocitrate dehydrogenase 1 (IDH1) mutations are the most common genetic abnormalities in low-grade gliomas and secondary glioblastomas. Glioma patients with these mutations had better clinical outcomes. However, the effect of IDH1 mutation on drug sensitivity is still under debate. MATERIALS AND METHODS: IDH1-R132H mutant cells were established by lentivirus. IDH1-R132H protein expression was confirmed by western blot. The expression of ataxia telangiectasia mutated (ATM) signaling pathway and apoptosis-related proteins were detected by immunofluorescence and western blot. Temozolomide (TMZ) induced cell apoptosis was detected by flow cytometry. Tumor cell proliferation was detected by Cell Counting Kit-8. In vivo nude mice were used to confirm the in vitro roles of IDH1 mutation. RESULTS: We established glioma cell lines that expressed IDH1-R132H mutation stably. We found that TMZ inhibited glioma cells proliferation more significantly in IDH1 mutant cells compared to wild type. The IC(50) of TMZ in IDH1-R132H mutant group was less than half that of wild-type group (p < 0.01). TMZ significantly induced more DNA damage (quantification of γH2AX expression in IDH1 mutation vs. wild type, p < 0.05) and apoptosis (quantification of AnnexinV(+)propidium iodide(−) cells in IDH1 mutation versus wild type, p < 0.01) in IDH1 mutant gliomas compared to wild-type gliomas. The ATM-associated DNA repair signal was impaired in IDH1 mutant cells. Inhibiting the ATM/checkpoint kinase 2DNA repair pathway further sensitized IDH1 mutant glioma cells to chemotherapy. We found that IDH1 mutation significantly inhibited tumor growth in vivo (the tumor size was analyzed statistically, p < 0.05). Moreover, we confirmed that gliomas with IDH1 mutation were more sensitive to TMZ in vivo compared to wild type significantly and the results were consistent with the in vitro experiment. CONCLUSION: These results provide evidence that combination of TMZ and ATM inhibitor enhances the antitumor effect in IDH1 mutant gliomas. |
format | Online Article Text |
id | pubmed-8053882 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Korean Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-80538822021-04-29 Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma Lin, Lin Cai, Jinquan Tan, Zixiao Meng, Xiangqi Li, Ruiyan Li, Yang Jiang, Chuanlu Cancer Res Treat Original Article PURPOSE: Isocitrate dehydrogenase 1 (IDH1) mutations are the most common genetic abnormalities in low-grade gliomas and secondary glioblastomas. Glioma patients with these mutations had better clinical outcomes. However, the effect of IDH1 mutation on drug sensitivity is still under debate. MATERIALS AND METHODS: IDH1-R132H mutant cells were established by lentivirus. IDH1-R132H protein expression was confirmed by western blot. The expression of ataxia telangiectasia mutated (ATM) signaling pathway and apoptosis-related proteins were detected by immunofluorescence and western blot. Temozolomide (TMZ) induced cell apoptosis was detected by flow cytometry. Tumor cell proliferation was detected by Cell Counting Kit-8. In vivo nude mice were used to confirm the in vitro roles of IDH1 mutation. RESULTS: We established glioma cell lines that expressed IDH1-R132H mutation stably. We found that TMZ inhibited glioma cells proliferation more significantly in IDH1 mutant cells compared to wild type. The IC(50) of TMZ in IDH1-R132H mutant group was less than half that of wild-type group (p < 0.01). TMZ significantly induced more DNA damage (quantification of γH2AX expression in IDH1 mutation vs. wild type, p < 0.05) and apoptosis (quantification of AnnexinV(+)propidium iodide(−) cells in IDH1 mutation versus wild type, p < 0.01) in IDH1 mutant gliomas compared to wild-type gliomas. The ATM-associated DNA repair signal was impaired in IDH1 mutant cells. Inhibiting the ATM/checkpoint kinase 2DNA repair pathway further sensitized IDH1 mutant glioma cells to chemotherapy. We found that IDH1 mutation significantly inhibited tumor growth in vivo (the tumor size was analyzed statistically, p < 0.05). Moreover, we confirmed that gliomas with IDH1 mutation were more sensitive to TMZ in vivo compared to wild type significantly and the results were consistent with the in vitro experiment. CONCLUSION: These results provide evidence that combination of TMZ and ATM inhibitor enhances the antitumor effect in IDH1 mutant gliomas. Korean Cancer Association 2021-04 2020-10-13 /pmc/articles/PMC8053882/ /pubmed/33070553 http://dx.doi.org/10.4143/crt.2020.506 Text en Copyright © 2021 by the Korean Cancer Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Lin, Lin Cai, Jinquan Tan, Zixiao Meng, Xiangqi Li, Ruiyan Li, Yang Jiang, Chuanlu Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma |
title | Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma |
title_full | Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma |
title_fullStr | Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma |
title_full_unstemmed | Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma |
title_short | Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma |
title_sort | mutant idh1 enhances temozolomide sensitivity via regulation of the atm/chk2 pathway in glioma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053882/ https://www.ncbi.nlm.nih.gov/pubmed/33070553 http://dx.doi.org/10.4143/crt.2020.506 |
work_keys_str_mv | AT linlin mutantidh1enhancestemozolomidesensitivityviaregulationoftheatmchk2pathwayinglioma AT caijinquan mutantidh1enhancestemozolomidesensitivityviaregulationoftheatmchk2pathwayinglioma AT tanzixiao mutantidh1enhancestemozolomidesensitivityviaregulationoftheatmchk2pathwayinglioma AT mengxiangqi mutantidh1enhancestemozolomidesensitivityviaregulationoftheatmchk2pathwayinglioma AT liruiyan mutantidh1enhancestemozolomidesensitivityviaregulationoftheatmchk2pathwayinglioma AT liyang mutantidh1enhancestemozolomidesensitivityviaregulationoftheatmchk2pathwayinglioma AT jiangchuanlu mutantidh1enhancestemozolomidesensitivityviaregulationoftheatmchk2pathwayinglioma |